## Supporting Information

Benchmarking bicontinuous nanospheres against polymersomes for *in vivo* biodistribution and dual intracellular delivery of lipophilic and water soluble payloads

Sean D. Allen $^{1\dagger}$ , Sharan Bobbala $^{2\dagger}$ , Nicholas B. Karabin $^2$ , Mallika Modak $^2$ , and Evan A. Scott $^{1,2,3,4,5*}$ 

<sup>&</sup>lt;sup>1</sup>Interdisciplinary Biological Sciences, Northwestern University, Evanston, USA.

<sup>&</sup>lt;sup>2</sup>Department of Biomedical Engineering, Northwestern University, Evanston, USA.


<sup>&</sup>lt;sup>3</sup>Chemistry of Life Processes Institute, Northwestern University, Evanston, USA.

<sup>&</sup>lt;sup>4</sup>Simpson Querrey Institute, Northwestern University, Chicago, USA.

<sup>&</sup>lt;sup>5</sup>Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA.


<sup>&</sup>lt;sup>†</sup>These authors contributed equally to this work.

<sup>\*</sup> Corresponding Author: <a href="mailto:evan.scott@northwestern.edu">evan.scott@northwestern.edu</a>




ntal Figur e 1. Nega tive Stain ed TEM **Imag** es of BCN **s**. (a) Low and (b) high magn ificati on


TEM images of BCNs. Scale bar for (a) represents 2000 nm, scale bar for (b) represents 500 nm.



Supplemental Figure 2. IVIS Organ-Level Biodistribution of PSs and BCNs 4 and 24 H Post IV Injection. Representative IVIS images for organs harvested from a PBS, PS, or BCN treated mouse, (a) 4 h or (b) 24 h post IV injection. Each representative mouse is set to its own radiant efficiency scaling, displayed on the far right of each row.



**Supplemental Figure 3. Flow Cytometric Assessment of Cell Population Uptake of PSs and BCNs 4 and 24 h Post IV Injection.** Nanoparticle uptake of PSs and BCNs 4 and 24 h after IV injection in C57BL6J female mice, showing immune cell populations in the spleen, blood, and liver. N = 3, error bars = S.E.M. Mφ = macrophages (CD45<sup>+</sup> CD3<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> F4/80<sup>+</sup>), Mo = Monocytes (CD45<sup>+</sup> CD3<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> CD11b<sup>+</sup> CD11c<sup>-</sup> Ly-6G<sup>-</sup> Ly-6G<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> CD3<sup>+/-</sup>.



**Supplemental Figure 4. Flow Cytometric Quantification of Cell Populations With and Without Treatment.** Comparison of cell populations in the (a) blood and (b) spleen, relative to all CD45<sup>+</sup> CD3<sup>-</sup> CD19<sup>-</sup> NK1.1<sup>-</sup> Ly-6G<sup>-</sup> cells for PBS-treated mice (both timepoints combined) and nanocarrier-treated mice (PS and BCN combined, timepoints separated). Error bars = S.D.

